Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513972 | 0.91 | CCR1 (0.52) | CCR1GAAKDM4EALDH1A1CXCR3 | |
| SCHEMBL25757907 | 0.89 | CCR1 (0.50) | CCR1GAAKDM4EALDH1A1CXCR3 | |
| SCHEMBL2579871 | 0.89 | CCR1 (0.52) | CCR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4652967 | 0.88 | PTGER1 (0.42) | CCR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8513975 | 0.87 | CCR1 (0.54) | CCR1GAAKDM4ECXCR3LMNA | |
| SCHEMBL1758546 | 0.87 | CCR1 (0.54) | CCR1GAAKDM4ECXCR3LMNA | |
| SCHEMBL25757726 | 0.85 | CCR1 (0.51) | CCR1GAAKDM4ECXCR3LMNA | |
| SCHEMBL1758419 | 0.84 | GAA (0.49) | CCR1GAAKDM4EALDH1A1CXCR3 | |
| SCHEMBL27863436 | 0.84 | CCR1 (0.53) | CCR1GAAKDM4ECXCR3LMNA | |
| SCHEMBL28799628 | 0.83 | CCR1 (0.50) | CCR1GAAKDM4EALDH1A1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228156-B | Fungicidal carboxamides | DU PONT | 2012-07-18 | — | — | CN | claimed |
| EP-2493886-B1 | HETEROARYL PIPERIDINE AND PIPERAZINE DERIVATES | BAYER CROPSCIENCE AG (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8586611-B2 | Fungicidal carboxamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-8501781-B2 | Heteroarylpiperidine and -piperazine derivatives | BAYER CROPSCIENCE AG (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2493886-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | Bayer CropScience AG (DE) | 2012-09-05 | — | — | EP | disclosed |
| CN-101228156-B | Fungicidal carboxamides | DU PONT | 2012-07-18 | — | — | CN | disclosed |
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-12-15 | — | — | US | disclosed |
| US-20110269712-A1 | Fungicidal Carboxamides | BISAHA JOHN JOSEPH | 2011-11-03 | — | — | US | disclosed |
| WO-2011051244-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2008091594-A2 | FUNGICIDAL MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1948649-A2 | FUNGICIDAL CARBOXAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007014290-A2 | FUNGICIDAL CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | CAT, DPM1, ERG28 | CCR1 4297/4885GAA 533/4885KDM4E 1783/4885 |
| US-20110269712-A1 | Fungicidal Carboxamides | NAT1, PFAS, CHRM1 | CCR1 1540/4885GAA 421/4885KDM4E 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.